Omeros Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Omeros Corporation Omeros Corporation (Nasdaq: OMER), founded in 1994 and headquartered in Seattle, Washington, operates as a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, addictive and compulsive disorders, and central nervous system conditions; its approved product OMIDRIA (phenylephrine and ketorolac intraocular solution 1%/0.3%) maintains pupil size and reduces postoperative pain in patients undergoing cataract surgery or intraocular lens replacement; lead pipeline candidates include the MASP-2 inhibitor narsoplimab (OMS721) under FDA review for hematopoietic stem cell transplant-associated thrombotic microangiopathy, the long-acting MASP-2 inhibitor OMS1029 in Phase 1, small-molecule inhibitors of MASP-2, MASP-3 and MASP-2/3, the PDE7 inhibitor OMS527 in clinical development for cocaine use disorder funded by the National Institute on Drug Abuse, PPAR gamma (PPARγ) agonists such as OMS405 for addiction disorders including opioids, nicotine and alcohol, GPR174 inhibitors and cellular therapies enhancing T-cell function for immuno-oncology applications, and other programs leveraging its proprietary GPCR platform for orphan and large-market indications with operations primarily in the United States. In recent developments, Omeros entered a definitive agreement in October 2025 with Novo Nordisk for the asset purchase and license of its clinical-stage MASP-3 inhibitor zaltenibart (OMS906) targeting paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy, providing up to $2.1 billion in upfront, milestone and royalty payments while retaining rights to certain preclinical MASP-3 programs; the company also announced agreements in May 2025 to acquire $80.5 million of its convertible senior notes due 2026 and convert an additional $10 million into common stock to strengthen its balance sheet ahead of potential narsoplimab commercialization.
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
Omeros Q1 Earnings Call Highlights
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Omeros Corporation Reports First Quarter 2026 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade
4 Medical Product Stocks to Buy From a Challenging Industry
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Brokerages
Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?
JPMorgan Chase & Co. Boosts Holdings in Omeros Corporation $OMER
Contrasting Omeros (NASDAQ:OMER) and Medtronic (NYSE:MDT)
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates
Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER)
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results